Biocryst Pharmaceuticals (BCRX) Income from Non-Controlling Interests (2024 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Income from Non-Controlling Interests of -$344000.0 for Q1 2026, down 394.02% on a QoQ basis from $117000.0 in Q4 2025, and down 121.94% year-over-year from $1.6 million in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$344000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 121.94% year-over-year to -$344000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$398000.0 (down 176.83% YoY) and the FY2025 annual result came in at -$209000.0, down 158.06% from the prior year.
- Income from Non-Controlling Interests was -$344000.0 for Q1 2026 at Biocryst Pharmaceuticals, down from $117000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.2 million in Q3 2024 and bottomed at -$426000.0 in Q4 2024.
- A 3-year average of -$21444.4 and a median of -$155000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 127.46% in 2025, while the deepest fall reached 154.05% in 2025.
- Biocryst Pharmaceuticals' Income from Non-Controlling Interests stood at -$426000.0 in 2024, then surged by 127.46% to $117000.0 in 2025, then sank by 394.02% to -$344000.0 in 2026.
- Business Quant data shows BCRX's Income from Non-Controlling Interests at -$344000.0 in Q1 2026, $117000.0 in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -344,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -344,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -188,000.00 |
| Mar 31, 2025 | -155,000.00 |
| Dec 31, 2024 | -426,000.00 |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | -74,000.00 |
| Mar 31, 2024 | -313,000.00 |